Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 22.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,098 shares of the biopharmaceutical company's stock after selling 18,237 shares during the quarter. Great Lakes Advisors LLC owned about 0.05% of Halozyme Therapeutics worth $3,065,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth approximately $29,000. Smartleaf Asset Management LLC increased its stake in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth approximately $69,000. Parkside Financial Bank & Trust increased its stake in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 322 shares during the last quarter. Finally, Centaurus Financial Inc. bought a new stake in Halozyme Therapeutics during the third quarter worth approximately $127,000. 97.79% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Piper Sandler boosted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Benchmark restated a "buy" rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Wells Fargo & Company dropped their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

Remove Ads

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company's stock, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 31,697 shares of company stock worth $1,754,451. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Trading Up 2.8 %

Shares of NASDAQ HALO traded up $1.76 during trading hours on Wednesday, reaching $64.30. The stock had a trading volume of 1,347,023 shares, compared to its average volume of 1,311,164. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The firm has a market cap of $7.92 billion, a price-to-earnings ratio of 18.75, a P/E/G ratio of 0.42 and a beta of 1.32. The business's fifty day moving average price is $57.53 and its two-hundred day moving average price is $54.61. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.